Question-and-Answer Session
Operator
(Operator Instructions) Your first question comes from Stephen Dunn – Jesup & Lamont.
Stephen Dunn – Jesup & Lamont
Can you give us a little color or guidance of when we would expect to see data from the multitude of phase II trials?
Steven King
As we allow the data to mature from the Docetaxel study, which we completed earlier this year, we do anticipate over the next few months to be able to give an update as those patients complete their full course of therapy, so I think with the patient enrolment in that study being completed, it’s a little easier to guess when we’ll have an update on the program. For the Carboplatin and Paclitaxel studies, clearly the next milestone will be completing patient enrolment in those two studies. Enrolment in the expanded cohort is now well underway so we should be completing that, I think, over the next few months time period, and hopefully later this year we’ll be able to give a meaningful update on how those patient followups are going and then what our tumor response rates look like. What I can say is that so far we think all three trials of have proceeded nicely, very happy with overseeing from the trails as a total, and again I think based on that data we have already really starting looking to the next set of studies because we certainly expect they are going to support further evaluations of these combinations.
Stephen Dunn – Jesup & Lamont
On DTRA program, they are doing viral hemorrhagic fevers and that’s kind of a pleural. I assume lots of fever is there because that’s what we saw in the Nature Medicine article. Are there any hemorrhagic fevers that go in? Is this like a broad program or is it really specifically lots of fever?
Steven King
Yes, the goal of the program is actually to look at Bavituximab as a broad-spectrum treatment for preventive for viral hemorrhagic fever, so definitely we will be looking at multiple different viral types, and I think it is one of the things that attracted the DTRA to the program was that the fact number one we were already in clinical studies with the drug so we had a little more proven technology and as you said really supported the facts that we had this broad spectrum potential because what they are really looking for is something to really potentially not just treat the known emerging viruses but new emerging virus that may come up.
- To read the full transcript on Seeking Alpha, click here »
